Abstract

of results Median CD4 282 cells/μl (IQR:252), HIV-1 VL 4.17 log10 (IQR 1.35), and duration of HIV infection 13 years. Number of NRTI, NNRTI and PI RAMs: 5 (IQR:4), 1 (IQR:1), and 6 (IQR:4), respectively. Patients exposed to LPV/r had received more HAART regimens (p < 0.001), PIs (p < 0.001), and NRTIs (p < 0.001). RAMs significantly associated with prior or current LPV/r exposure were: L10I/F (p = 0.02, p = 0.001), K20R (p = 0.023), L24I (p = 0.01), L33F (p < 0.001), M36I (p = 0.029), M46I/L (p = 0.023, p = 0.003), I47V (p = 0.022), G48V (p = 0.08), F53L (p = 0.017), I54V (p < 0.001), A71V (p < 0.001), G73S (p = 0.008), V82A (p < 0.001), I84V (p < 0.001), and L90M (p = 0.037). Two NRTI mutations were also associated with LPV/r failure: E44D (p = 0.002) and V118I (p = 0.048). L76V was found in only one sample. RAMs associated only with current (and not previous) LPV/r failure were: L33F, M36I, M46I, I47V, G48V, A71V, G73S, I84V, L90M. These RAMs are all included in the IAS-USA LPV/r list, except M36I and G48V, found to be associated with prior saquinavir use (p = 0.02 and p < 0.001, respectively). Mutations included in the IAS-USA list for LPV but not found to be associated with LPV/r previous or current failure: L10R/V, K20M, V32I, I47A, I50V, I54L/A/M/T/S, L63P, A71T, I76V, and V82F/T/S.

Highlights

  • Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf

  • We investigated the resistance mutations (RAMs) in patients with prior or current LPV/r failure

  • Patients exposed to LPV/r had received more HAART regimens (p < 0.001), PIs (p < 0.001), and NRTIs (p < 0.001)

Read more

Summary

Open Access

Address: 1University Hospital Germans Trias, Badalona, Spain, 2Universitat Politècnica de Catalunya, Barcelona, Spain, 3Hospital Sant Pau, Barcelona, Spain, 4Hospital Xeral Cies, Vigo, Spain and 5National Haemophilia Center, Tel Aviv, Israel. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf

Purpose of the study
Methods
Summary of results
Findings
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.